NT-proBNP - A potential predictor for restenosis after coronary intervention?;NT-proBNP - Ein möglicher prädiktorfür die restenose nach koronarintervention?

Medizinische Welt

Volumn 56, Issue 5, 2005, Pages 213-217

  El Mokhtari, Nour Eddine ^a   Reinecke, A ^a   Neudorf, S ^a   Plate, V ^a   Hubner R ^a   Lentz, S ^a   Lins, M ^a   Bruhn, H D ^a   Simon, R ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BNP; NT proBNP; PCI; Predictor; Restenosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; FOLLOW UP; HEART VENTRICLE FUNCTION; HUMAN; IMMUNOASSAY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROTEIN BLOOD LEVEL; RESTENOSIS;

EID: 20844445489     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bibbins-Domingo K et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003; 108: 2987-92.
2. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001; 51: 442-9.
3. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002; 44: 293-321.
4. Cowie MR et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
5. de Lemos JA, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
6. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990; 81: 748-56.
7. Goetze JP et al. Increased cardiac BNP expression associated with myocardial ischemia. Faseb J 2003; 17: 1105-7.
8. Holmes DR, Jr. et al. Restenosis after percutaneous transluminal coronary angioplasty (PICA): a report from the PICA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53: 77C-81C.
9. Hunt PJ et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287-96.
10. Hunt SA et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-13.
11. Jernberg T et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40: 437-45.
12. Kikuta K et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996; 132: 101-7.
13. Lesperance J et al. Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials. Am Heart J 1993; 125: 1394-408.
14. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 2001; 19: 557-71.
15. Marumoto K, Hamada M and Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995; 88: 551-6.
16. McDonagh TA et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
17. Morita E et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
18. Muders F et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-9.
19. Nagaya N et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21-8.
20. Pfisterer M et al. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. J Am Coll Cardiol 1993; 22: 1446-54.
21. Popma JJ, van den Berg EK, Dehmer GJ. Long-term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 62: 1298-9.
22. Remme WJ and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
23. Richards AM et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
24. Sabatine MS et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3.
25. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85.
26. Serruys PW et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-71.
27. Talwar S et al. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000; 84: 421-4.
28. Yasue H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.